Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Three Or More Carbocyclic Rings Patents (Class 514/33)
  • Patent number: 5723149
    Abstract: The invention relates to the use of Medicago saponins for the preparation of cosmetic or pharmaceutical compositions. The invention provides for the incorporation of 0.01% to 5% by weight of a saponin or a corresponding sapogenin, or a plant extract in which it is present, originating in particular from lucerne leaves or roots. The invention makes it possible to promote renewal of the epidermis, stimulate hair regrowth or delay hair loss, or else to combat the effects of ageing on the state of the skin and scalp, as is evident from the FIGURE.
    Type: Grant
    Filed: February 5, 1996
    Date of Patent: March 3, 1998
    Assignee: LVMH Recherche
    Inventors: Frederic Bonte, Alain Meybeck, Georges Massiot
  • Patent number: 5723448
    Abstract: Administration of argininosuccinate synthetase activity reducing agents, e.g., argininosuccinate synthetase induction blocking agents (e.g., antibiotics that bind to DNA sequences present in the upstream regulatory region of the argininosuccinate synthetase gene, such as mithramycin) and argininosuccinate synthetase inhibitors (e.g., L-citrulline antagonists such as methyl citrulline and L-aspartate antagonists such as D-aspartate) is useful to prevent or treat sepsis or cytokine-induced systemic hypotension, is useful in the treatment of sepsis or cytokine-induced systemic hypotension to restore vascular sensitivity to the effects of .alpha..sub.1 -adrenergic agonists, and is useful to suppress an immune response, e.g., in treating inflammation. In one embodiment, certain argininosuccinate synthetase activity reducing agents are used together with arginine antagonists to treat sepsis or cytokine induced hypotension.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: March 3, 1998
    Assignee: The Medical College of Wisconsin Research Foundation
    Inventors: Steven S. Gross, Owen W. Griffith
  • Patent number: 5696096
    Abstract: The present invention relates to new antifungal compounds having the formula ##STR1## wherein R.sup.1 is hydrogen, methyl, or hydroxymethyl; R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen and C.sub.1-5 alkyl; and R.sup.4 is selected from the group consisting of .beta.-L-xylosyl, .beta.-D-ribosyl, .alpha.-L-arabinosyl, .beta.-D-chinovosyl, .beta.-D-fucosyl, and .beta.-D-glucosyl; with the proviso that when R.sup.1 is methyl or hydroxymethyl, and one of R.sup.2 or R.sup.3 is methyl, R.sup.4 is not .beta.-D-glucosyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 1990
    Date of Patent: December 9, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shimpei Aburaki, Haruhiro Yamashita, Takayuki Naito
  • Patent number: 5650398
    Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 22, 1997
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani, Joanne Recchia
  • Patent number: 5646124
    Abstract: The present invention relates to a method of treating a patient suffering from a neoplastic disease state comprising administering to said patient an effective antineoplastic amount of N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine in conjunctive therapy with an effective antineoplastic amount of a cytotoxic agent selected from the group consisting of an antineoplastic vinca alkaloid, an antineoplastic antibiotic, an antineoplastic antimetabolite and an antineoplastic platinum coordination complex, wherein a synergistic antineoplastic effect results.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 8, 1997
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Nellikunja J. Prakash, Terry L. Bowlin
  • Patent number: 5639735
    Abstract: Hayumicin compounds, obtainable by cultivation of a strain of Actinomadura sp. designated ATCC 55432, and analogs of these compounds. The novel compounds have antitumor as well as antibiotic, particularly antibacterial, activity.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: June 17, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rolf Menzel, Scott T. Taylor, Mitsuaki Tsunakawa, Keiichi Numata, Tamotsu Furumai
  • Patent number: 5624911
    Abstract: Methods for treating mammals to reduce pain and/or reduce inflammation are described based on administering to the mammals synthetic ether derivatives of pseudopterosin having the formula: ##STR1## wherein A is an alkyl, aryl or amide group having from 2 to 20 carbon atoms, R.sub.1, R.sub.2 and R.sub.3 are hydrogen or an acyl residue (--COR) having from 1 to 6 carbon atoms, R.sub.4 is hydrogen or --CH.sub.2 OH and R.sub.5 is a hydrocarbon having from 1 to 10 carbon atoms. Also disclosed are synthetic compositions having the above general formula which are useful in the described method.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 29, 1997
    Assignee: The Regents of the University of California
    Inventors: William H. Fenical, Robert S. Jacobs
  • Patent number: 5609882
    Abstract: This invention relates to an etoposide preparation containing an etoposide composition comprising an etoposide, polyvinylpyrrolidone, and water-soluble cellulose ether derivative wherein the proportion of the respective components is about 0.25 to 2 parts by weight for polyvinylpyrrolidone and about 0.0028 to 0.2 parts by weight for the water-soluble cellulose ether derivative per 1 part by weight of the etoposide, and about 10 to 20% (w/w) for the etoposide in the whole amount of the composition.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: March 11, 1997
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Minoru Aoki, Minoru Nakada, Yuichi Yazawa, Gen'ichi Izu, Takashi Terada
  • Patent number: 5597808
    Abstract: Methods of promoting wound healing and the growth and proliferation of keratinocytes, fibroblasts and endothelial cells are disclosed. These methods comprise contacting a wound with an effective wound healing amount of a composition comprising a pseudopterosin or pseudopterosin derivative.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 28, 1997
    Assignee: OsteoArthritis Sciences, Incorporated
    Inventors: Howard B. Haimes, Pablo A. Jimenez
  • Patent number: 5580857
    Abstract: The use of active gibberellins for the preparation of a pharmaceutical composition for the treatment of prostatitis. The method results in a decrease in prostate mass.
    Type: Grant
    Filed: January 24, 1994
    Date of Patent: December 3, 1996
    Inventor: Per Oden
  • Patent number: 5565436
    Abstract: A production stimulator of nerve growth factor contains a new cyathane derivative of the form ##STR1## where R is either CHO or CH.sub.2 OH.
    Type: Grant
    Filed: October 11, 1994
    Date of Patent: October 15, 1996
    Assignee: Kagome Kabushiki Kaisha
    Inventors: Hirokazu Kawagishi, Fumihiro Ojima, Kenji Okamoto, Hideki Sakamoto, Yukio Ishiguro
  • Patent number: 5545625
    Abstract: Administration of argininosuccinate synthetase activity reducing agents, e.g., argininosuccinate synthetase induction blocking agents (e.g., antibiotics that bind to DNA sequences present in the upstream regulatory region of the argininosuccinate synthetase gene, such as mithramycin) and argininosuccinate synthetase inhibitors (e.g., L-citrulline antagonists such as methyl citrulline and L-aspartate antagonists such as D-aspartate) is useful to prevent or treat sepsis or cytokine-induced systemic hypotension, is useful in the treatment of sepsis or cytokine-induced systemic hypotension to restore vascular sensitivity to the effects of .alpha..sub.1 -adrenergic agonists, and is useful to suppress an immune response, e.g., in treating inflammation. In one embodiment, certain argininosuccinate synthetase activity reducing agents are used together with arginine antagonists to treat sepsis or cytokine induced hypotension.
    Type: Grant
    Filed: December 12, 1994
    Date of Patent: August 13, 1996
    Assignee: The Medical College of Wisconsin Research Foundation, Inc.
    Inventors: Steven S. Gross, Owen W. Griffith
  • Patent number: 5525480
    Abstract: The present invention provides N- and O-substituted aminophenol derivatives of the general formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, G and L are as hereinbefore defined. The present invention also provides intermediates for the preparation of these aminophenol derivatives of general formula (I), as well as the use of the aminophenol derivatives of general formula (I) for the determination of hydrolases, as well as for the preparation of agents for carrying out determinations of hydrolysis.
    Type: Grant
    Filed: June 9, 1994
    Date of Patent: June 11, 1996
    Assignee: Boehringer Mannheim GmbH
    Inventors: Gerd Zimmermann, Dieter Mangold
  • Patent number: 5514663
    Abstract: This invention relates to a pharmaceutical laxative composition in unit dosage form, for peroral administration of sennosides to a human or other animal subject, comprising a safe and effective amount of sennosides in a rapidly dissolving matrix; and a proximal colonic delivery carrier which effects release of said sennosides substantially near the junction between the small intestine and the colon or within the colon of said subject. This invention also involves methods for providing laxation for humans and other animals in need thereof by peroral administration of such compositions.
    Type: Grant
    Filed: October 19, 1993
    Date of Patent: May 7, 1996
    Assignee: The Procter & Gamble Company
    Inventor: Kenneth G. Mandel
  • Patent number: 5480873
    Abstract: Pharmaceutical compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, hydroxyl, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, acyloxy, --O-glucoside, optionally substituted phenyl or optionally substituted phenyl-C.sub.1-4 alkoxy;R.sup.3 istetrazolyl, orand R.sup.4 and R.sup.5 are each hydrogen, hydroxy, acyloxy, nitro, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halo, optionally substituted phenyl, --SO.sub.3 H or --NR'R" where R' and R" are each hydrogen or C.sub.1-4 alkyl;provided that when R.sup.3 is --CR'R".CHR'"CO.sub.2 H or tetrazolyl, R.sup.1 and R.sup.2 are each hydroxyl, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, acyloxy, --O-glucoside, optionally substituted phenyl or optionally substituted phenyl C.sub.1-4 alkoxy; andor a pharmaceutically acceptable salt or ester thereof.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: January 2, 1996
    Assignee: Lilly Industries Limited
    Inventors: Michael Brunavs, Colin P. Dell, David R. Dobson, Peter T. Gallagher, Terence A. Hicks, William M. Owton, Colin W. Smith
  • Patent number: 5459152
    Abstract: Indole compounds substituted at the 3-position by a 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]thiazole, 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]oxazole, or 7-carbonyl(pyridin-3-yl)pyrrolo[1,2-c]pyrrole group are potent antagionists of PAF and are useful in the treatment of PAF-related disorders including asthma, shock, respiratory distress syndrome, acute inflammation, transplanted organ rejection, gastrointesinal ulceration, allergic skin diseases, delayed cellular immunity, parturition, fetal lung maturation, and cellular differentiation.
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: October 17, 1995
    Assignee: Abbott Laboratories
    Inventors: James B. Summers, Steven K. Davidsen, James H. Holms, Daisy Pireh, H. Robin Heyman, Michael B. Martin, Douglas H. Steinman, George S. Sheppard, George M. Carrera, Jr.
  • Patent number: 5443829
    Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: August 22, 1995
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
  • Patent number: 5391544
    Abstract: New cyathane derivatives shown by Formula (1) or (2) given below have the effect of stimulating production of nerve growth factors and antimicrobial effects: ##STR1## where R is either CHO or CH.sub.2 OH.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: February 21, 1995
    Assignee: Kagome Kabushiki Kaisha
    Inventors: Hirokazu Kawagishi, Fumihiro Ojima, Kenji Okamoto, Hideki Sakamoto, Yukio Ishiguro
  • Patent number: 5364843
    Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are piperazinyl benzyl compounds such as 1-[.alpha.-(4-Chlorophenyl)-3-methoxybenzyl]-4-allylpiperazine dihydrochloride.
    Type: Grant
    Filed: June 10, 1992
    Date of Patent: November 15, 1994
    Assignee: Burroughs Wellcome Co.
    Inventor: Ann C. King
  • Patent number: 5346897
    Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 10, 1992
    Date of Patent: September 13, 1994
    Assignee: Burroughs Wellcome Co.
    Inventor: Ann C. King
  • Patent number: 5338728
    Abstract: Disclosed are novel pradimicin compounds which possess antifungal activity and, preferably, improved water solubility. The compounds of the invention are prepared by modifying the 4'-amino or 4'-alkylamino moieties of known pradimicin compounds.
    Type: Grant
    Filed: August 14, 1992
    Date of Patent: August 16, 1994
    Assignee: Bristol-Myers Squibb
    Inventors: Hajime Kamachi, Minoru Hirano, Shinji Masuyoshi
  • Patent number: 5326753
    Abstract: The present invention relates to a freeze-dried preparation comprising (1) about 5 to about 50 W/W% of a non-volatile acid and/or a salt thereof, (2) about 10 to about 95 W/W% of 4-O-(2-deoxy-2-dimethylamino-4,6-O-ethylidene-.beta.-D-glucopyranosyl)-4'- demethyl-4-epipodophyllotoxin hydrochloride and (3) 0 to about 85 W/W% of at least one sugar as a stabilizer.
    Type: Grant
    Filed: May 20, 1992
    Date of Patent: July 5, 1994
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Kazuo Ohtsuki, Taka'aki Ohkuma
  • Patent number: 5273965
    Abstract: Methods for enhancing the transport of pharmacologically active substances across mucous membranes of an animal by administration of pharmaceutical compositions comprising modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract. Also disclosed are modified saponins having reduced irritability wherein the fatty acid moiety is removed by hydrolysis or the aldehyde group is reduced. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: December 28, 1993
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani
  • Patent number: 5227370
    Abstract: The present invention provides pradimicin analogs which exhibit improved water solubility relative to parent compounds. These novel agents are useful in treatment of fungal infections.
    Type: Grant
    Filed: December 3, 1991
    Date of Patent: July 13, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hajime Kamachi, Seiji Iimura, Satsuki Okuyama, Shimpei Aburaki, Takayuki Naito, Yasutsugu Ueda, Leonard B. Crast, Jr., Amarendra B. Mikkilineni
  • Patent number: 5208238
    Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are 2-(aminoethylamino) pyridines such as (E)-3-(6-(N-(2-Dimethylaminoethyl)-4-methoxybenzylamino)-2-pyridyl)acrylic acid.
    Type: Grant
    Filed: June 10, 1992
    Date of Patent: May 4, 1993
    Assignee: Burroughs Wellcome Company
    Inventor: Ann C. King
  • Patent number: 5194371
    Abstract: The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960-producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).
    Type: Grant
    Filed: July 31, 1991
    Date of Patent: March 16, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tamotsu Furumai, Masami Hatori, Masatoshi Kakushima, Chiharu Ikeda, Kyoichiro Saitoh, Seikichi Kobaru
  • Patent number: 5190949
    Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 10, 1992
    Date of Patent: March 2, 1993
    Assignee: Burroughs Wellcome Company
    Inventor: Ann C. King
  • Patent number: 5183808
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: February 19, 1992
    Date of Patent: February 2, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5166139
    Abstract: Complexes of saponins from Centella asiatica, terminalia sp. and Terminalia sericea and relevant aglycons with phospholipids are described. The saponins may be asiaticoside, madecassicoside and sericoside. The molar ratio of phospholipids to saponins is from 0.5 to 2. The phospholipids are selected from the group consisting of soy lecithins, phospholipids from bovine or swine brain or cutis, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine in which the acyl groups can be the same or different and are mostly derived from palmitic, stearic, oleic, linoleic, linolenic acids. Pharmaceutical compositions and the method of treatment are also described.
    Type: Grant
    Filed: January 18, 1991
    Date of Patent: November 24, 1992
    Assignee: Indena, S.p.A.
    Inventors: Ezio Bombardelli, Gianfranco Patri, Roberto Pozzi
  • Patent number: 5120717
    Abstract: Pharmaceutical compositions containing at least one of benanomicins A and B and their salts are now provided, which are useful to inhibit the infection of human T-cells with HIV, namely a virus causative of acquired human immunodeficiency syndrome (AIDS). Thus, benanomicins A and B as well as their salts are useful as antiviral agent against HIV.
    Type: Grant
    Filed: August 16, 1989
    Date of Patent: June 9, 1992
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Tomio Takeuchi, Shinichi Kondo, Hiroo Hoshino
  • Patent number: 5118671
    Abstract: Complexes formed between aescin, cholesterol or .beta.-sitosterol and phospholipids are described. The molar ratio of phospholipids to aescin/.beta.-sitosterol or cholesterol is from 0.5 to 2. The phospholipids are selected from the group of soy or egg lecithins, phospholipids from bovine or swine brain or cutis, phosphatidylcholine, phospatidylserine, phosphatidylethanolamine in which the acyl groups may be the same or different and are mostly derived from palmitic, stearic, oleic, linoleic, linolenic acids, for instance, pharmaceutical compositions and a method for producing an anti-inflammatory effect in an animal are also described.
    Type: Grant
    Filed: December 19, 1990
    Date of Patent: June 2, 1992
    Assignee: Indena S.p.A.
    Inventors: Ezio Bombardelli, Gianfranco Patri, Roberto Pozzi
  • Patent number: 5093323
    Abstract: As a new compound is now provided N-acetylbenanomicin B which is useful as an antifungal agent and also as antiviral agent for inhibiting infection of human T-cell with HIV, namely a virus causative of acquired human immunodeficiency syndrome. N-acetylbenanomicin B may be prepared by acetylation of 4"-amino group of benanomicin B which is fermentatively produced by a new microorganism, MH193-16F4 strain of actinomycetes.
    Type: Grant
    Filed: December 29, 1989
    Date of Patent: March 3, 1992
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Tomio Takeuchi, Shinichi Kondo, Shuichi Gomi, Hiroo Hoshino
  • Patent number: 5091371
    Abstract: As a new antifungal and antiviral antibiotic is provided benanomicin A 4"'-O-sulfate or a salt thereof having formula (I) ##STR1## wherein M.sup.1 denotes a mono-valent alkali metal atom or a di-valent alkaline earth metal atom or a hydrogen atom and A denotes an organic base; n is zero when M.sup.1 is an alkali metal atom or alkaline earth metal atom but n is 1 or zero when M.sup.1 is a hydrogen atom, and M.sup.2 denotes a hydrogen atom or an alkali metal atom or an alkaline earth metal atom. This new compound is useful as antifungal agent to treat fungal infections in mammals and as antiviral agent to inhibitingly treat HIV.
    Type: Grant
    Filed: June 29, 1990
    Date of Patent: February 25, 1992
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Tomio Takeuchi, Shinichi Kondo, Daishiro Ikeda
  • Patent number: 5066645
    Abstract: The present invention provides antitumor 4'-Demethylepipodophyllotoxin glycosides characterized by the fact that the glycoside moiety is altrose.
    Type: Grant
    Filed: September 1, 1989
    Date of Patent: November 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: Takeshi Ohnuma, Hideaki Hoshi, Hideo Kamei, Takayuki Naito
  • Patent number: 5057540
    Abstract: Substantially pure saponins are disclosed. The saponins of the present invention are useful as immune adjuvants. Disclosed as well are immune response-provoking compositions comprising an antigen in admixture with the substantially pure saponins.
    Type: Grant
    Filed: August 27, 1990
    Date of Patent: October 15, 1991
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Dante J. Marciani
  • Patent number: 5053395
    Abstract: Disclosed herein are pradimicin amides which are active as antifungel agents.
    Type: Grant
    Filed: March 24, 1989
    Date of Patent: October 1, 1991
    Assignee: Bristol-Myers Company
    Inventors: Maki Nishio, Seiji Iimura, Toshikazu Oki
  • Patent number: 5041424
    Abstract: Phosphate derivatives of 4'-demethylepipodophyllotoxin glucosides are novel antitumor agents and the salts thereof offer the pharmaceutical advantage of high water solubility.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: August 20, 1991
    Assignee: Bristol-Myers Company
    Inventors: Mark G. Saulnier, Peter D. Senter, John F. Kadow
  • Patent number: 5024838
    Abstract: A composition for the treatment of skin injuries is described including an antiseptic, a sapogenine, a proteolytic enzyme and a suitable vehicle. The composition is directly applied on the injury, forming a film which isolates and protects same from infection and suppresses pain. The film is self-adherent and transparent, which allows inspection of the healing injury, without the need of removing the film, as with bandages. The composition is antiseptic and microbiocidal, helps cicatrization and produces a biochemical debridement. The film allows the natural motility of the injury zone and produces a compression which helps to decrease or prevent edema. The film also allows the passage of air, preventing the production of anaerobiosis, decreasing the output of liquids, and preventing, in large injuries, dehydration and loss of electrolytes. The film can be removed merely by wetting.
    Type: Grant
    Filed: May 10, 1988
    Date of Patent: June 18, 1991
    Inventor: Vicente Parrilla
  • Patent number: 4999341
    Abstract: The association of chitin or chitosan with soy saponins in an orally administered composition has appetite moderating and antigastritis activity. The objectionable side effects of the two active ingredients are also eliminated in the composition.
    Type: Grant
    Filed: September 27, 1989
    Date of Patent: March 12, 1991
    Inventor: Antonio Ferro
  • Patent number: 4992425
    Abstract: Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.
    Type: Grant
    Filed: June 7, 1988
    Date of Patent: February 12, 1991
    Assignee: Bristol-Myers Company
    Inventors: Maki Nishio, Yosuke Sawada, Takeo Miyaki, Toshikazu Oki
  • Patent number: 4987125
    Abstract: A method of preparing a triterpenoids from Ilex pubescens which includes extracting the Ilex pubescens roots with organic solvent to an initial extract and converting the initial extract to the triterpenoids exhibiting antithrombotic activity on humans or mammals. Also, a pharmaceutical composition containing an effective antithrombotic amount of the triterpenoids from the Ilex pubescens.
    Type: Grant
    Filed: June 29, 1988
    Date of Patent: January 22, 1991
    Assignee: Cheil Sugar & Co., Ltd.
    Inventors: Yong N. Han, Byung H. Han, Soung K. Baik, Tae H. Kim
  • Patent number: 4975278
    Abstract: This invention relates to a novel method for the delivery of cytotoxic drugs to tumor cells by the administration of a tumor-specific antibody-enzyme conjugate that binds to the tumor cells, and the additional administration of a prodrug that is converted at the tumor site, in the presence of the antibody-bound enzyme, to an active cytotoxic drug. According to preferred embodiments of this invention, antibody-enzyme conjugates containing the enzyme, alkaline phosphatase ("AP"), have been used in conjunction with the novel prodrug, etoposide-4'-phosphate or 7-(2'-aminoethyl phosphate)mitomycin or a combination thereof, to effect killing of tumor cells. According to another embodiment of the invention, an antibody-enzyme conjugate containing the enzyme, penicillin V amidase ("PVA"), has been used in conjunction with a novel prodrug, N-(p-hydroxyphenoxyacetyl)adriamycin to effect killing of tumor cells.
    Type: Grant
    Filed: June 29, 1988
    Date of Patent: December 4, 1990
    Assignee: Bristol-Myers Company
    Inventors: Peter D. Senter, Mark G. Saulnier, Joseph P. Brown, David E. Kerr
  • Patent number: 4961927
    Abstract: An aqueous solution comprises lysozyme hydrochloride, dipotassium glycyrrhizinate, at least one selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium phosphate, potassium phosphate, sodium citrate, potassium citrate, sodium carbonate and potassium carbonate and water, has a pH of 5 to 9 and is useful for eye drops.
    Type: Grant
    Filed: November 25, 1987
    Date of Patent: October 9, 1990
    Assignee: Eisai Co., Ltd.
    Inventor: Yoshio Kogure
  • Patent number: 4960755
    Abstract: Disclosed herein are N-alkyl derivatives of antibiotics BU-3608, BU-3608 B, C, D and E as well as the corresponding desxylosyl compounds. These novel compounds are useful as antifungal agents.
    Type: Grant
    Filed: July 19, 1988
    Date of Patent: October 2, 1990
    Assignee: Bristol-Myers Company
    Inventors: Maki Nishio, Masatoshi Kakushima, Masataka Konishi, Toshikazu Oki
  • Patent number: 4958010
    Abstract: Novel antitumor epipodophyllotoxin glucoside lactam derivatives are prepared by first converting the lactone ring of the parent compound to the open-chain trans-hydroxy hydrazide, condensing the hydrazide with a carbonyl compound to form the corresponding hydrazone, and finally cyclizing the trans-hydroxy hydrazone using diethylazodicarboxylate and triphenylphosphine.
    Type: Grant
    Filed: January 30, 1989
    Date of Patent: September 18, 1990
    Assignee: Bristol-Myers Company
    Inventors: John F. Kadow, Dolatrai M. Vyas
  • Patent number: 4952563
    Abstract: The invention relates to a new application form of low molecular weight alkali metal huminates wherein the waterfree low molecular weight alkali metal huminate is bound to an inorganic, hydrogen bridge forming, carrier material such as titanium dioxide, aluminum oxide, highly dispersed silicium dioxide, or clay.
    Type: Grant
    Filed: March 1, 1988
    Date of Patent: August 28, 1990
    Assignee: Rutgerswerke AG
    Inventors: Bernhard Seubert, Helmut Beilharz, Werner Fickert, Gunter Jeromin, Ulrich Spitaler
  • Patent number: 4935445
    Abstract: Improvement in method for treating tumors sensitive to treatment with anti-tumor agents employing Norverapamil.
    Type: Grant
    Filed: March 28, 1988
    Date of Patent: June 19, 1990
    Inventor: Stephen Merry
  • Patent number: 4921840
    Abstract: The invention relates to a synthetic preparation of alkali metal salts of low molecular weight humic acids wherein multi-valent phenols are oxidized in a weakly alkaline aqueous medium at a temperature in the range of 15.degree. to 40.degree. C. Subsequently, the reaction mixture is adjusted to a pH value ranging between 6.2 and 7.2 and/or buffered. The low molecular alkali metal huminate is then purified through purification means including preparatory chromotography, ultra-filtration, ultra-centrifugation, or electrodialysis and separated from undesirable by-products.
    Type: Grant
    Filed: March 1, 1988
    Date of Patent: May 1, 1990
    Assignee: Rutgerswerke AG
    Inventors: Bernhard Seubert, Helmut Beilharz, Werner Fickert, Gunter Jeromin, Ulrich Spitaler
  • Patent number: 4918059
    Abstract: Alkali metal or ammonium salts of humic acids, referred to as alkali metal huminates of low molecular weight, obtained by slurrying humic-containing matter in alkaline or ammoniacal aqueous solutions, separating the resulting suspension from coarse solid matter and, through centrifugation, freeing the solution from extremely fine solid materials and high molecular weight huminates. The resulting solution is neutralized and buffered at a pH value ranging from 6.2 to 7.2, and is again purified through centrifugation. From this solution, a low molecular weight fraction is separated. The resulting alkali metal huminates of low molecular weight are useful as therapeutic agents in wound healing and for use in highly effective synthetic mud baths.
    Type: Grant
    Filed: March 1, 1988
    Date of Patent: April 17, 1990
    Assignee: Rutgerswerke AG
    Inventors: Bernhard Seubert, Helmut Beilharz, Werner Fickert, Gunter Jeromin, Ulrich Spitaler
  • Patent number: 4888419
    Abstract: This invention relates to novel 3'-demethoxy epipodophyllotoxin glucosides, their use as anti-tumor agents, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 31, 1987
    Date of Patent: December 19, 1989
    Assignee: Bristol-Myers Company
    Inventors: Mark G. Saulnier, Dolatrai M. Vyas